Suppr超能文献

酮康唑在肿瘤疾病患者中的药代动力学。

Pharmacokinetics of ketoconazole in patients with neoplastic diseases.

作者信息

Maksymiuk A W, Levine H B, Bodey G P

出版信息

Antimicrob Agents Chemother. 1982 Jul;22(1):43-6. doi: 10.1128/AAC.22.1.43.

Abstract

Twenty-seven patients with advanced malignancies were given 200 mg of ketoconazole orally every 6 or 12 h. Blood samples were collected during these intervals and after the last dose to determine plasma concentrations and half-lives. The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h. Plasma concentrations rose significantly in patients on the every-6-h schedule. Concentrations were more variable in patients on the every-12-h schedule, and changes in mean plasma concentrations after 7 and 14 days were not significant. Half-lives ranged from 1.3 to 11.6 h in individual patients. The mean half-life for all patients studied was 3.7 +/- 0.6 h on day 1. The calculated area under the curve was 12.0 +/- 4.7 micrograms-h/ml on day 1; it increased after 7 and 14 days of administration (every-6-h schedule), suggesting plasma binding or wide drug distribution or both. Saturation of storage compartments is also suggested. Less than 1% of the administered dose was recoverable as active drug from the urine over 6 h.

摘要

27例晚期恶性肿瘤患者每6或12小时口服200毫克酮康唑。在这些间隔期间以及最后一剂后采集血样,以测定血浆浓度和半衰期。初始剂量后2小时测得的平均血浆浓度为1.7±1.1微克/毫升,6小时为0.9±0.2微克/毫升,8小时为0.7±0.4微克/毫升。每6小时给药一次的患者血浆浓度显著升高。每12小时给药一次的患者浓度变化更大,7天和14天后平均血浆浓度变化不显著。个体患者的半衰期为1.3至11.6小时。研究的所有患者第1天的平均半衰期为3.7±0.6小时。第1天计算的曲线下面积为12.0±4.7微克-小时/毫升;给药7天和14天后(每6小时给药一次方案)增加,提示血浆结合或药物广泛分布或两者兼有。也提示储存室饱和。在6小时内,从尿液中回收的给药剂量中活性药物不到1%。

相似文献

2
Distribution of oral ketoconazole to vaginal tissue.口服酮康唑在阴道组织中的分布。
Eur J Clin Pharmacol. 1982 Oct;23(4):331-3. doi: 10.1007/BF00613615.
4
Impairing effect of food on ketoconazole absorption.食物对酮康唑吸收的损害作用。
Antimicrob Agents Chemother. 1982 May;21(5):730-3. doi: 10.1128/AAC.21.5.730.
9
Ketoconazole therapy for systemic fungal infections: inadequacy of standard dosage regimens.
Am Rev Respir Dis. 1982 Jul;126(1):171-4. doi: 10.1164/arrd.1982.126.1.171.
10
Ketoconazole.酮康唑
Lancet. 1982 Feb 27;1(8270):517. doi: 10.1016/s0140-6736(82)91494-5.

引用本文的文献

1
Systemic absorption of ketoconazole from vaginal pessaries.阴道栓剂中酮康唑的全身吸收。
Br J Clin Pharmacol. 1984 Feb;17(2):173-5. doi: 10.1111/j.1365-2125.1984.tb02334.x.
2
Influence of food on the pharmacokinetics of ketoconazole.食物对酮康唑药代动力学的影响。
Antimicrob Agents Chemother. 1984 Jan;25(1):1-3. doi: 10.1128/AAC.25.1.1.
4
Clinical pharmacokinetics of systemic antifungal drugs.全身性抗真菌药物的临床药代动力学。
Clin Pharmacokinet. 1983 Jan-Feb;8(1):17-42. doi: 10.2165/00003088-198308010-00002.
9
The pharmacokinetics of ketoconazole after chronic administration in adults.
Eur J Clin Pharmacol. 1987;33(5):531-4. doi: 10.1007/BF00544251.
10
Clinical pharmacokinetics of ketoconazole.酮康唑的临床药代动力学
Clin Pharmacokinet. 1988 Jan;14(1):13-34. doi: 10.2165/00003088-198814010-00002.

本文引用的文献

1
Cardiorespiratory toxicity due to miconazole.咪康唑引起的心肺毒性。
Ann Intern Med. 1980 Sep;93(3):432-3. doi: 10.7326/0003-4819-93-3-432.
3
Liquid chromatographic assay of ketoconazole.酮康唑的液相色谱测定法。
Antimicrob Agents Chemother. 1981 Jan;19(1):110-3. doi: 10.1128/AAC.19.1.110.
4
Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole.
Rev Infect Dis. 1980 Jul-Aug;2(4):656-60. doi: 10.1093/clinids/2.4.656.
7
Unusual serum lipoprotein abnormality induced by the vehicle of miconazole.
N Engl J Med. 1977 Mar 3;296(9):497-9. doi: 10.1056/NEJM197703032960907.
9
Oral therapy for experimental coccidioidomycosis with R41 400 (ketoconazole), a new imidazole.
Am Rev Respir Dis. 1978 Oct;118(4):715-21. doi: 10.1164/arrd.1978.118.4.715.
10
Fungal infections in the cancer patient.
S Afr Med J. 1977 Dec 10;52(25):1009-15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验